3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2H-chromene-2-carboxamide hydrochloride | 1048981-15-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2H-chromene-2-carboxamide hydrochloride
• 英文别名: 6-hydroxy-N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxamide;hydrochloride
• CAS: 1048981-15-2
• 化学式: C₂₃H₃₆N₂O₄*ClH
• 分子量: 441.011
• InChiKey: CRAXWRXFACBXPR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.35
• 重原子数：
  30
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  82
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-N-(1-nitroxy-4-amino-2,2,6,6-tetramethylpiperidin-4-yl)-chromane-2-carboxamide 在 盐酸 作用下， 以 甲醇 、 异丙醇 为溶剂， 反应 2.0h， 以83.9%的产率得到3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2H-chromene-2-carboxamide hydrochloride
  参考文献：
  名称：

  Drug Resistance Reversal In Neoplastic Disease

  摘要：

  本发明涉及用于阻止或逆转肿瘤性疾病化疗耐药效应的化合物、组合物和方法。具体描述了羟胺的使用。

  公开号：

  US20080200405A1

文献信息

• HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE
  申请人：Patil Ghanshyam

  公开号：US20080280890A1

  公开（公告）日：2008-11-13

  The present disclosure provides compounds that include hydroxylamines of formula I or II, pharmaceutical compositions, and methods for their use. The methods utilize hydroxylamine compounds and/or their pharmaceutical compositions for the treatment of angiogenesis, hepatitis, complement-mediated pathologies, drusen-mediated pathologies, macular degeneration and certain other ophthalmic conditions, inflammation, arthritis, and related diseases and for the inhibition of complement activation.

  本公开提供了包括式I或II的羟胺化合物、制药组合物以及它们的使用方法。该方法利用羟胺化合物及/或其制药组合物治疗血管生成、肝炎、补体介导的病理、色斑介导的病理、黄斑变性和某些其他眼科疾病、炎症、关节炎和相关疾病，并抑制补体激活。
• Hydroxylamine compounds and methods of their use
  申请人：Colby Pharmaceutical Company

  公开号：EP2620429A1

  公开（公告）日：2013-07-31

  The present disclosure provides compounds that include hydroxylamines of formula I or II, pharmaceutical compositions, and methods for their use. The methods utilize hydroxylamine compounds and/or their pharmaceutical compositions for the treatment of angiogenesis, hepatitis, complement-mediated pathologies, drusen-mediated pathologies, macular degeneration and certain other ophthalmic conditions, inflammation, arthritis, and related diseases and for the inhibition of complement activation.

  本公开提供了包括式 I 或式 II 的羟胺化合物、药物组合物及其使用方法。这些方法利用羟胺化合物和/或其药物组合物治疗血管生成、肝炎、补体介导的病变、褐斑介导的病变、黄斑变性和某些其他眼科疾病、炎症、关节炎和相关疾病以及抑制补体活化。
• DRUG RESISTANCE REVERSAL IN NEOPLASTIC DISEASE
  申请人：Othera Holding, Inc.

  公开号：EP2120942A2

  公开（公告）日：2009-11-25
• [EN] DRUG RESISTANCE REVERSAL IN NEOPLASTIC DISEASE<br/>[FR] INVERSION DE LA RÉSISTANCE À DES MÉDICAMENTS DANS UNE MALADIE NÉOPLASIQUE
  申请人：OTHERA HOLDING INC

  公开号：WO2008101195A2

  公开（公告）日：2008-08-21

  (EN) The present invention is directed to compounds, compositions, and methods for halting or reversing the effects of chemoresistance in neoplastic diseases. In particular the use of hydroxylamines is described.(FR) La présente invention concerne des composés, des compositions et des procédés servant à stopper ou inverser les effets de la chimiorésistance dans des maladies néoplasiques. En particulier, l'invention concerne l'utilisation d'hydroxylamines.
• [EN] HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE<br/>[FR] COMPOSÉS D'HYDROXYLAMINE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：OTHERA HOLDING INC

  公开号：WO2008103613A2

  公开（公告）日：2008-08-28

  [EN] The present disclosure provides compounds that include hydroxylamines of formula (I) or (II), pharmaceutical compositions, and methods for their use. The methods utilize hydroxylamine compounds and/or their pharmaceutical compositions for the treatment of angiogenesis, hepatitis, complement-mediated pathologies, drusen-mediated pathologies, macular degeneration and certain other ophthalmic conditions, inflammation, arthritis, and related diseases and for the inhibition of complement activation.
  [FR] La présente invention concerne des composés qui comprennent des hydroxylamines de formule I ou II, des compositions pharmaceutiques et leurs procédés d'utilisation. Les procédés utilisent des composés d'hydroxylamine et/ou leurs compositions pharmaceutiques pour le traitement de l'angiogenèse, de l'hépatite, de pathologies médiées par le complément, de pathologies médiées par des druses, d'une dégénérescence maculaire et de certaines autres affections ophtalmiques, d'une inflammation, d'une arthrite et de maladies associées et pour l'inhibition de l'activation du complément.